secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001104659-25-122272
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet announces positive Phase 1 PK data for denifanstat/resmetirom combo in MASH
--------------------------------------------------------------------------------

- Phase 1 PK trial (NCT07216313) of denifanstat + resmetirom in 40 healthy adults met objectives; combination well-tolerated, no SAEs.
- PK data support further development; no drug-drug interaction signals observed; no treatment discontinuations.
- Company plans Phase 2 proof-of-concept trial in MASH F4 fibrosis patients in 2H 2026 pending regulatory consultation.
- Global license agreement with TAPI (TEVA affiliate) to develop once-daily fixed-dose combination tablet for Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925122272/0001104659-25-122272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925122272/tm2533462d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-122272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer